Verastem Oncology

What Verastem Oncology does

Verastem Oncology (legal name Verastem, Inc.) is a commercial-stage biopharmaceutical company headquartered in Needham, Massachusetts, developing small-molecule therapies for patients with RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK, an FDA-accelerated approved combination of avutometinib (a first-in-class RAF/MEK clamp) and defactinib (a selective FAK inhibitor), which received approval in May 2025 as the first and only treatment indicated for KRAS-mutated recurrent low-grade serous ovarian cancer. The pipeline is anchored by VS-7375, an oral KRAS G12D dual ON/OFF inhibitor being advanced through three Phase 2 registration-directed trials in pancreatic, non-small cell lung, and colorectal cancers.

The company generates revenue through U.S. specialty pharmacy distribution of AVMAPKI FAKZYNJA CO-PACK, supported by the Verastem Cares patient access program providing insurance navigation and financial assistance. The go-to-market is a focused specialty oncology field sales model targeting oncologists and gynecologic oncology prescribers. With a headcount of 51-100, Verastem operates as a lean commercial-stage biotech, leveraging IQVIA for outsourced commercialization and Tempus AI for companion diagnostic development. Strategic capital has been raised through multiple public offerings and private placements, totaling approximately $90M in November 2025 alone, with cash, cash equivalents, and investments of $205M ($234M pro forma) as of December 31, 2025.

The business model is a single-asset commercial launch plus a pipeline of Phase 2 oncology assets, with FY2025 net product revenue of $30.9M against a GAAP net loss of $209.5M. Future revenue is contingent on the approval trajectory of VS-7375 across multiple KRAS G12D-mutated solid tumor indications, supported by FDA Fast Track Designations in pancreatic cancer (July 2025) and NSCLC (June 2026). The competitive position is anchored by first-mover regulatory approval in KRAS-mutated LGSOC and a novel mechanism targeting the most prevalent KRAS mutation in human cancers, though the company faces significant execution risk on commercialization ramp, pipeline development, and continued capital needs.

Name

Verastem Oncology

Legal name

Verastem, Inc.

Website

https://verastem.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

101–250 employees

Short description

Verastem Oncology is a commercial-stage biopharmaceutical company that develops small-molecule therapies for RAS/MAPK pathway-driven cancers, currently marketing the FDA-approved AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated ovarian cancer and advancing VS-7375 through Phase 2 trials in pancreatic, lung, and colorectal cancers.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industries

Gynecologic Oncology (HLAKAFAF), Gastrointestinal Oncology (HLAKAFAK), Digestive Oncology (GI Cancer Care) (HLAKAEAF)

Keywords

• Targeted oncology therapies
• RAS MAPK inhibitors
• Small molecule cancer drugs
• KRAS mutation treatments
• Rare cancer therapeutics

Headquarters

HQ city

Needham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Product Revenue - AVMAPKI FAKZYNJA CO-PACK: Verastem generates revenue through the sale of its FDA-approved AVMAPKI FAKZYNJA CO-PACK combination therapy for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). The company reports net product revenues from U.S. commercial sales.
2. Future Revenue Potential - VS-7375: The company is developing VS-7375, an oral KRAS G12D inhibitor, through registration-directed Phase 2 trials in pancreatic, lung, and colorectal cancers with potential for future commercial revenue if approved.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

Verastem Oncology is a biopharmaceutical company that develops and commercializes small molecule drugs targeting the RAS/MAPK signaling pathway in cancer cells. Its lead commercial product, AVMAPKI FAKZYNJA CO-PACK (avutometinib plus defactinib), is an FDA-approved combination therapy for KRAS-mutated recurrent low-grade serous ovarian cancer. The company's pipeline includes VS-7375, an oral KRAS G12D (ON/OFF) inhibitor in registration-directed trials for pancreatic, lung, and colorectal cancers.

Product overview

Verastem Oncology is a biopharmaceutical company focused on developing medicines for patients with RAS/MAPK pathway-driven cancers. The company's portfolio consists of FDA-approved and investigational small molecule drugs targeting critical signaling pathways in cancer. The approved product AVMAPKI FAKZYNJA CO-PACK (avutometinib plus defactinib) received FDA accelerated approval in May 2025 for KRAS-mutated recurrent low-grade serous ovarian cancer. The company is also advancing VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, through Phase 2 registration-directed trials for pancreatic cancer, non-small cell lung cancer, and colorectal cancer. Verastem's pipeline includes avutometinib (RAF/MEK clamp) and defactinib (FAK inhibitor) used in combination regimens, as well as discovery programs from its collaboration with GenFleet Therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

• AVMAPKI FAKZYNJA CO-PACK: FDA-approved combination therapy of avutometinib capsules and defactinib tablets for KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC).
• Verastem Cares

Products and services

• AVMAPKI FAKZYNJA CO-PACK FDA-approved co-pack therapy consisting of avutometinib capsules and defactinib tablets for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. This is the first FDA-approved treatment specifically indicated for KRAS-mutated recurrent LGSOC.
• VS-7375 (GFH375) Investigational oral KRAS G12D (ON/OFF) inhibitor designed to engage KRAS G12D directly while sparing wild-type KRAS signaling across both active (GTP-bound) and inactive (GDP-bound) states. In development for KRAS G12D-mutated solid tumors including pancreatic cancer (PDAC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). VS-7375 is also known as GFH375 in China.
• Avutometinib (VS-6766) First-in-class RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF, creating more complete and durable anti-tumor response through maximal RAS pathway inhibition. Avutometinib blocks both RAF and MEK in a single molecule and offers an intermittent twice-weekly oral dosing schedule.
• Defactinib (VS-6063) Selective focal adhesion kinase (FAK) inhibitor that inhibits parallel pathway signaling and has demonstrated synergy with avutometinib. Used in combination therapy for RAS pathway-driven cancers including low-grade serous ovarian cancer and pancreatic cancer.

Quantifiable outcome

• 86% overall survival rate at 6 months in first-line metastatic pancreatic cancer (RAMP 205 trial)
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• ErascacoreStrategic or Co-development Partner · 23 June 2026Collaboration announced to evaluate VS-7375 in combination with Erasca's ERAS-0015 pan-RAS molecular glue in advanced KRAS G12D-mutant solid tumors, pending execution of a definitive agreement.
• Tempus AIminorStrategic or Co-development Partner · 17 October 2025Collaboration for companion diagnostic development using Tempus AI platform to support development of treatments for KRAS-mutant ovarian cancer, as part of the global oncology market projected to grow at 15.2% CAGR through 2028.
• IQVIAminorImplementation/ SI/ Consulting Partner · 13 May 2025Strategic commercial collaboration with IQVIA for the launch of AVMAPKI FAKZYNJA CO-PACK, providing commercialization and market access support.
• GenFleet TherapeuticscoreStrategic or Co-development Partner · 1 January 2023Verastem Oncology entered into a collaboration agreement with GenFleet Therapeutics for three discovery programs, with exclusive options to license three compounds upon successful completion of predetermined Phase 1 milestones. VS-7375 (known as GFH375 in China) is the lead discovery program. Verastem holds development and commercialization rights outside of GenFleet territories (mainland China, Hong Kong, Macau, and Taiwan). GenFleet's IND for GFH375 was approved in June 2024, and they are conducting Phase 1/2 and Phase 3 clinical trials in China.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Revolution Medicines: Revolution Medicines is a direct peer developing RAS(ON) inhibitors targeting KRAS G12D, G12V, G12X, and other variants. Like Verastem, it focuses on small-molecule RAS pathway inhibitors for solid tumors and competes directly in the KRAS G12D space with VS-7375.
• Erasca: Erasca is a direct peer developing pan-RAS molecular glues and MAP kinase pathway inhibitors. Erasca recently partnered with Verastem to combine ERAS-0015 with VS-7375, reflecting direct competitive overlap in the KRAS G12D treatment landscape.
• Relay Therapeutics: Relay Therapeutics develops precision oncology drugs including RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor, and is advancing KRAS-targeted programs. Relay's precision oncology focus and similar stage of clinical development makes it a comparable mid-cap oncology peer.
• Black Diamond Therapeutics: Black Diamond Therapeutics develops precision oncology medicines against oncogene-driven cancers, including MAP kinase pathway targets. Its focus on RAS-driven cancers and small-molecule approach directly mirrors Verastem's strategy.
• Day One Biopharmaceuticals: Day One Biopharmaceuticals develops targeted therapies for oncology with a similar focus on rare cancer indications and has an approved product (Ojemda). Its commercial-stage oncology focus and rare disease strategy parallel Verastem's profile.
• Foghorn Therapeutics: Foghorn Therapeutics develops medicines targeting the chromatin regulatory system, including programs addressing RAS-driven cancers through chromatin-based mechanisms. Like Verastem, it is a clinical-stage oncology company focused on hard-to-treat cancers.
• SpringWorks Therapeutics: SpringWorks Therapeutics is a commercial-stage rare oncology company with approved therapy Ogsiveo for desmoid tumors. Its rare cancer focus and recent commercial launch experience make it a comparable peer to Verastem's LGSOC franchise.
• Mirati Therapeutics: Mirati Therapeutics developed Krazati (adagrasib), a KRAS G12C inhibitor, before being acquired by Bristol-Myers Squibb. Mirati's KRAS-focused portfolio and pipeline overlap with VS-7375 and avutometinib mechanisms make it a closely comparable peer prior to acquisition.

Broad incumbents

• Amgen: Amgen markets Lumakras (sotorasib), the first FDA-approved KRAS G12C inhibitor, and is a broad oncology incumbent with vastly larger resources. Amgen previously collaborated with Verastem on RAMP 203 before discontinuation due to evolving treatment landscape.
• Bristol-Myers Squibb: BMS acquired Mirati Therapeutics for $4.8B and now markets Krazati (adagrasib), a KRAS G12C inhibitor. As a broad oncology incumbent, BMS represents both a competitor in KRAS space and a potential acquisition partner for Verastem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/VerastemOncolog
• LinkedInlinkedin.com/company/verastemoncology

Revenue estimate

Valuation estimate

Number of profiles

Profiles22 records

Funding overview

Funding rounds16 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verastem Oncology